查看文章

SAT-230 Anticoagulant treatment for atrial fibrillation and decompensation rate in patients with liver cirrhosis I. Girleanu1, A. Trifan1, O. Stoica1, L. Huiban1, C. Stanciu2.] †œGr. T Popa" University of Medicine and Pharmacy, Gastroenterology, Iasi, Romania; 2Institute of Gastroenterology and Hepatology, Gastroenterology, Iasi, Romania Email:[email protected] Background and Aims: Anticoagulant treatment in patients with liver cirrhosis (LC) is still controversial. Recent studies demonstrated that anticoagulant treatment could reduce decompensation and mortality rates in cirrhotic patients. Our aim was to evaluate decompensation rate in patients with LC and atrial fibrillation treated with acenocoumarol for thrombotic events prophylaxis. Method: The study group included patients diagnosed with compensated liver cirrhosis and atrial fibrillation treated with an oral anticoagulant (acenocoumarol), admitted in a tertiary …